SAN CARLOS, Calif., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity…
– Company ended the quarter with $53.8 million in cash – Driving continued progress across diversified pre-clinical and clinical development…
DALLAS, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new…
SEC declared Effectiveness of Vickers’s registration statement on Form S-4Extraordinary General Meeting of Vickers Vantage Corp. I shareholders to approve…
Company to complete and submit responses to FDA clinical hold Continues to study leronlimab in other HIV-related, NASH, and oncology…
SAN CARLOS, Calif., Oct. 28, 2022 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity…
Continued strong growth in Q3 with key regulatory milestones achieved Paris, October 28, 2022 Q3 2022 sales growth of 9.0%…
JUPITER, Fla., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI),…
NEW YORK, Oct. 27, 2022 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced…
Year-over-year revenue grows 5%, operating profit up 5%, non-GAAP operating profit up 4%Note: A webcast of ResMed’s conference call will be available…